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Misleading Information 
on the Properties of Vitamin C
Steve Hickey, Hilary Roberts
The Cochrane review by Douglas et al. [1], which is 
referenced in the Best Practice article by Douglas and Hemilä 
[2], covers 60 years of research into vitamin C and the 
common cold. However, the review omits pharmacokinetic 
data that invalidate the conclusion that vitamin C is 
ineffective. This conclusion is not derivable from the data 
presented.
The dual-phase pharmacokinetics of vitamin C are 
described by the dynamic ﬂ  ow model [3,4]. Low gram-level 
intakes of ascorbate, leading to blood plasma levels below 70 
µM/l, have a half-life of 8–40 days. Higher gram-level intakes 
have a plasma half-life of 30 minutes [3]. A large oral dose 
raises blood plasma levels brieﬂ  y: they reach a peak after two 
to three hours, before decaying back to baseline. Frequent 
repeated doses allow sustained high plasma levels of about 
250 µM/l [4,5].
Douglas and Hemilä reviewed intakes that transiently raise 
plasma ascorbate levels above 70 µM/l. A single dose does 
not raise the median level [6,7]. Daily supplements would, 
thus, not increase disease resistance to any great degree [3,4]. 
Single or double doses daily will not increase background 
plasma levels, regardless of the magnitude of the dose [6,7]. 
Since plasma ascorbate is at background level for the majority 
of the day, effects will be minimal. 
There is widespread confusion about nutritional and 
pharmacological levels of supplementation [3]. Linus 
Pauling, typically, described nutritional gram-level doses able 
to provide a degree of disease prevention [8]. By contrast, 
pharmacological doses used for treatment are, at minimum, 
an order of magnitude larger and involve frequent doses. 
The doses should be at intervals of three hours or less [3]. 
Treatment doses are described by Cathcart’s paper on 
titration to bowel tolerance [9]. To treat the onset of a cold, 
the therapy is perhaps a minimum of 10 g of oral ascorbic 
acid, followed by at least 2 g each hour [3,4]. 
Douglas and Hemilä give a misleading impression by 
not making it clear that the doses they consider are not 
pharmacological. They claim that the results of one study, 
giving an 8-g dose at the start of symptoms, are tantalising and 
deserve further assessment. However, once this single dose 
has been excreted, the protective effects will be lost. During 
illness, ascorbate is depleted rapidly and higher oral intakes 
are tolerated—up to 200 g per day [9]. It would be surprising 
if this 8-g dose had a large effect.
Studies on ascorbate require appropriate doses. Douglas 
and Hemilä have only conﬁ  rmed that 60 years of vitamin 
C research has largely been wasted because of confusion 
between nutritional and pharmacological intakes, and 
because of a misunderstanding of the pharmacokinetics. It is 
essential that high-dose studies take into account ascorbate’s 
dual-phase pharmacokinetics. The dosing regime should 
allow sustained high plasma levels to be achieved. The claim 
that vitamin C cannot prevent or cure the common cold is 
both premature and unwarranted.  
Steve Hickey (radicalascorbate@yahoo.com)
Manchester Metropolitan University
Manchester, United Kingdom
Hilary Roberts
Manchester, United Kingdom
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Narrow Scope of Vitamin C Review
William Sardi
Covering 60 years of research without mentioning a paper that 
highlights ﬂ  aws in the literature, in a review, should negate 
any conclusion. In the Cochrane review by Douglas et al. [1], 
which is referenced in the Best Practice article by Douglas 
and Hemilä [2], there was no mention of the revealing paper 
published last year by Padayatty et al. [3], which shows that 
three-times greater blood concentration can be achieved 
with an oral dose of vitamin C than previously thought 
possible. Since viruses increase the demand for ascorbic acid, 
the oral doses used in the reviewed studies appear trivial, 
and would not be expected to produce any positive effect. 
Compare human oral dose studies to what animals synthesize 
throughout the day. It is obvious that a single dose of a water-
soluble vitamin, regardless of the number of milligrams 
consumed, will not elevate blood plasma levels enough to 
produce a preventive or therapeutic effect.  
William Sardi
Knowledge of Health
San Dimas, California, United States of America
E-mail: bsardi@aol.com
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Authors’ Reply
The responses to our Best Practice article [1] by Hickey and 
Roberts [2], and by Sardi [3], make the same point, namely, 
that a recent pharmacokinetic study reported that frequent 
oral intakes of vitamin C would be necessary to elevate plasma 
ascorbic acid levels to the point where they believe it would 
have a pharmacological impact. Both authors suggest that the 
conclusions of our Cochrane review [4] are ﬂ  awed because all 
of the placebo-controlled trials that have been carried out so 
far have used, for both prophylaxis and therapy, one to three 
doses per day of vitamin C, ranging from 200 mg daily to as 
much as 8 g in a single daily dose.
We have not, as our critics imply, concluded that vitamin 
C, in the doses used in trials reported in the literature, has no 
effect on the common cold. On the contrary, our evidence 
indicated that in marathon runners and in those exposed 
to high physical or cold stress, a substantial prophylactic 
effect was observed. And in the general population using 
regular vitamin C prophylaxis, common cold duration 
was consistently shortened, but the level of shortening was 
relatively trivial.
We do not consider the vitamin C and the common cold 
relationship closed. Nor are we persuaded by the arguments 
of these three critics that frequent, large doses would 
necessarily result in substantially greater beneﬁ  ts than earlier 
trials have demonstrated. 
We consider that it may be useful to distinguish between 
(a) prophylactic supplementation for people who are in good 
health and (b) therapeutic supplementation for people who 
have an infection. The kidneys reabsorb essentially all vitamin 
C when the dietary intake is below 60–100 mg/day, and the 
vitamin C level in leukocytes is saturated by approximately 
100 mg/day [5]; in this respect, we doubt that prophylactic 
supplementation of healthy people, using doses higher than 
those in the published trials, might be expected to beneﬁ  t 
the general healthy population. On the other hand, there is 
evidence indicating that common cold infection decreases the 
vitamin C level in leukocytes, suggesting changes in vitamin 
C metabolism [6], and, in this respect, there seems to be a 
rationale to study the effects of supplementation on people 
infected with the common cold using even higher doses.
To this point, the claim that these two letters make has not 
been reported in properly conducted randomized controlled 
trials of either therapy or prophylaxis. We look forward to 
incorporating such trials, when they have been carried out, in 
future versions of the Cochrane review. Meanwhile, we stand 
ﬁ  rmly by the conclusions reported in our article.  
Harri Hemilä (harri.hemila@helsinki.ﬁ  )
University of Helsinki
Helsinki, Finland
Robert M. Douglas
Australian National University
Canberra, Australia
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Secondary Schizophrenia
Dave Hambidge
May I respectfully highlight a potential confounding factor to 
interpreting an otherwise excellent and provoking study by 
Saha et al. [1].
In their recent overview of secondary schizophrenia 
(deﬁ  ned as “a disparate range of brain disorders that can, 
uncommonly, give rise to schizophrenia like symptomology” 
[2]), Hyde and Lewis [2] concluded that, overall, there 
was a prevalence rate of 5%–8% for psychoses of likely 
identiﬁ  able organic etiology amongst a series of relatively 
unselected patients. They suggest screening procedures 
in new cases of psychosis, including schizophrenia, with a 
battery of blood tests, a urine drug screen (UDS), and an 
electroencephalogram (EEG) as ﬁ  rst-line investigations.
Between September 2000 and November 2003, I 
interviewed and studied the medical records of 56 patients 
in northwest England, who were appealing against detention 
under the Mental Health Act (1983), and who had been 
admitted for the ﬁ  rst time within the last ten years [3]. They 
were all referred to me by their solicitors to prepare Legal 
Aid/Legal Services Commission–funded independent reports 
for their Mental Health Review Tribunal hearings. For 
each patient, I recorded which of the organic investigations 
suggested by Hyde and Lewis, if any, had been undertaken.
Of the 56 patients, ten were being detained for the ﬁ  rst 
time (three females and seven males, detained on average 
for 39 weeks) and 13 had been detained for over one year 
(two females and 11 males, detained on average for 106 
weeks). Whilst all except two of the 56 patients had some 
combination of blood tests recorded, 55% did not have a 
UDS and 83% did not have an EEG. Syphilis serology was 
examined for in only two patients of the latter group and 
none of the former. Therefore, my ﬁ  ndings suggest that 
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secondary schizophrenias may not be investigated for in 
most detained patients with a schizophrenia-like illness in 
England. 
As secondary schizophrenias are present in 5%–8% of such 
cases, some of the variability in rates found by these authors 
must be related to the differing diagnostic rigour used to 
exclude secondary causes.  
Dave Hambidge
Staffordshire, United Kingdom
E-mail: Cotlow9@aol.com
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Authors’ Reply: Measurement Errors in Schizophrenia 
Epidemiology
The letter from Hambidge highlights the heterogeneous 
nature of schizophrenia [1]. In order to diagnose 
schizophrenia, modern diagnostic criteria require the 
exclusion of other general somatic conditions that can mimic 
psychotic symptoms. Compliance with screening protocols 
designed to identify these disorders varies widely, even in 
developed countries. We agree with the correspondent 
that some studies included in our recent systematic review 
[2] would have probably included individuals who were 
subsequently found to have “secondary schizophrenia” (i.e., 
false positives). Thus, this issue would slightly inﬂ  ate the 
prevalence estimate. The inappropriate inclusion of false 
positives is only one of a very long list of methodological 
factors that contribute to imprecision in the estimation of 
the incidence and prevalence of schizophrenia. The critical 
issue for the research community is how best to partition out 
measurement error from “true” variations in the incidence or 
prevalence of schizophrenia. In the absence of more reﬁ  ned 
phenotypes for the many different disorders that contribute 
to the syndrome of schizophrenia (e.g., by the use of yet-to-
be-identiﬁ  ed biomarkers), standard epidemiological studies 
of the incidence and prevalence of schizophrenia may have 
reached their limits of precision.  
John McGrath (john_mcgrath@qcsr.uq.edu.au)
University of Queensland
Wacol, Queensland, Australia
Sukanta Saha
Joy Welham
David Charles Chant
Queensland Centre for Mental Health Research
Wacol, Queensland, Australia
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Response to Stampfer Commentary
David F. Williamson
Stampfer’s recent Perspective [1] on the paper by Sørensen 
et al. [2] appropriately acknowledges the challenges inherent 
in using observational epidemiology to determine the impact 
of weight loss on life expectancy. However, his case that the 
data of Sørensen et al. do not support their conclusion that 
intentional weight loss may be hazardous is based, in part, on 
erroneous statements about the study. 
Stampfer suggests that “reverse causation” could account 
for the ﬁ  ndings of Sørensen et al. because he believes they 
did not do a “lagged” analysis in which deaths that occur 
in the ﬁ  rst few years after follow-up are excluded. In the 
statistical analysis, however, Sørensen et al. describe using 
two separate fully adjusted models: one for the ﬁ  rst ﬁ  ve 
years of follow-up and one for the period thereafter, and 
they also reported mortality hazard ratios (HRs) associated 
with intentional weight loss during each period. Because so 
few deaths occurred in the ﬁ  rst ﬁ  ve years of follow-up, the 
estimated mortality HR for intentional weight loss during this 
period (6.26) had such a wide conﬁ  dence interval (0.33–118) 
that it was essentially meaningless. However, after excluding 
the ﬁ  rst ﬁ  ve years of follow-up data, Sørensen et al. still found 
a clinically and statistically signiﬁ  cant association between 
intentional weight loss and death during the remaining 13 
years of follow-up: HR = 1.88 (conﬁ  dence interval, 1.05–3.39). 
Stampfer indicates that the authors differentiated only 
between current smokers and nonsmokers and, thus, 
inappropriately combined never smokers with past smokers. 
In their methods, however, Sørensen et al. reported that they 
originally used four categories (never smoker, occasional 
smoker, former regular smoker, and current smoker) to 
code the smoking status of the study’s participants, before 
recoding smoking status as a dichotomous yes-or-no variable. 
However, as Sørensen et al. described in their statistical 
analysis, they analyzed their models using both of the coding 
methods to determine whether recoding resulted in residual 
confounding. Because they found no residual confounding, 
they chose to report results only from the model with the 
simpler, dichotomous coding of smoking status. 
Stampfer also argues that the best way to remove residual 
confounding by smoking is to “simply exclude current and 
past smokers” [1]. This exclusionary approach for smoking 
has been previously examined in a methodological study 
that utilized statistical simulation, with data from 15 diverse 
observational studies of body weight and mortality [3]. 
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The study concluded that eliminating smokers from the 
datasets prior to analysis produces results similar to those 
expected from the elimination of numerically similar random 
proportions of the datasets prior to analysis [3]. Thus, the 
practice of excluding smokers in studies of weight loss and 
mortality is highly questionable.  
David F. Williamson
Centers for Disease Control and Prevention
Atlanta, Georgia, United States of America
E-mail: drw1@cdc.gov
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Author’s Reply
Williamson states that, in my Perspective [1], I erred in 
pointing out that Sørensen et al. [2] differentiated only 
between current smokers and nonsmokers. As Williamson 
notes in his letter [3], the point raised is precisely the 
analysis presented by the authors. Adequate treatment 
for cigarette smoking is crucial. Williamson relies on a 
computer simulation to suggest that treatment is not 
important, but the plain facts demonstrate otherwise. 
Computer simulations are, of course, totally dependent on 
the underlying assumptions. Ample empirical data, coupled 
with strong biological knowledge, reinforce the importance 
of smoking as a confounding factor in studies of body 
weight and mortality. For example, in our own analysis, the 
link between overweight and mortality risk was substantially 
obscured by cigarette smoking, and emerged clearly when 
never smokers were analyzed separately [4]. The reasons 
for this are simple. Cigarette smoking is associated in many 
populations with a lower body mass index, and with higher 
mortality rates. Moreover, cigarette smoking causes several 
adverse health conditions that lead to lower body weight 
and higher mortality risk, such as chronic pulmonary 
disease and congestive heart failure. Individuals may often 
live with these conditions for many years, so that lagged 
analyses (conducted by Sørensen et al., as pointed out by 
Williamson) that exclude early mortality, though useful, are 
insufﬁ  cient by themselves to deal fully with this problem. 
Williamson appears to miss the most important point. 
This is simply not a study of the consequences of intentional 
weight loss, and can be illustrated by way of a quiz (see Table 
1): using data from the Sørensen paper, can the reader guess 
which is the intentional weight loss group? 
Group A declared an intention to lose weight, but the 
actual weight changes in the two groups were virtually 
indistinguishable. Do Williamson and Sorensen et al. 
seriously entertain the hypothesis that this difference in 
weight change caused an 88% increase in all-cause mortality 
rate? Clearly individuals declaring intent to lose weight 
differ from those who do not. However, it seems implausible 
to attribute the differences in mortality rate to the tiny 
differences in weight change.  
Meir Stampfer 
Harvard School of Public Health 
Boston, Massachusetts, United States of America
E-mail: mstampfe@hsph.harvard.edu
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Tamoxifen and the Singing Voice
Andrew Herxheimer
My remark, in my recent Essay in PLoS Medicine [1], that 
deepening of the voice occurs with long-term use of 
tamoxifen for breast cancer needs qualiﬁ  cation. 
Several colleagues have rightly pointed out that the 
evidence for the effect is less clear than I implied: it comes 
from women who have experienced it [2], but there have 
been no controlled studies. A change in voice was looked 
for and not found among effects spontaneously reported in 
large trials of tamoxifen, but this was not speciﬁ  cally asked 
about and might well have been missed. It is also recognised 
that the voice sometimes becomes deeper during or after 
menopause, in the absence of tamoxifen. 
To convey the uncertainty of the facts, I wish to amend 
my statement as follows: “The irreversible deepening of the 
voice that has been reported to occur with long-term use of 
tamoxifen for breast cancer is an example of a side effect that 
prescribers, manufacturers, and drug regulators seem to have 
considered trivial and have not investigated.”  
Andrew Herxheimer
United Kingdom Cochrane Centre
Table 1. Data from Sørensen et al. [2]
Variable Group A Group B
Median 6-y weight change + 0.33 kg/m2 + 0.31 kg/m2
Percent with weight loss 38% 38%
Percent with weight gain 34% 31%
DOI: 10.1371/journal.pmed.0020326.t001
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Acquired Geﬁ  tinib-Resistant Mutation 
of EGFR in a Chemonaive Lung 
Adenocarcinoma Harboring 
Geﬁ  tinib-Sensitive Mutation L858R
Chien-Hung Gow, Jin-Yuan Shih, Yih-Leong Chang, 
Chong-Jen Yu
The research article by Pao et al. [1] provides important 
new information addressing three patients with acquired 
resistance to geﬁ  tinib or erlotinib in progressing tumors 
containing a secondary mutation, leading to the substitution 
of methionine for threonine at position 790 (T790M) in 
exon 20. However, all of the patients received systemic 
chemotherapy prior to geﬁ  tinib or erlotinib therapy, and 
the original lung tissue was obtained long before epidermal 
growth factor receptor (EGFR) inhibitors were used. We 
describe a chemonaive patient with geﬁ  tinib-sensitive lung 
adenocarcinoma harboring L858R. The tumor progressed 
and developed an additional T790M mutation after nine 
months of geﬁ  tinib treatment.
A 56-year-old female who had never smoked presented 
with nonproductive cough for one month. Her chest 
radiography revealed a mass in the right lower lung (RLL) 
(Figure 1A). Chest tomography (CT) conﬁ  rmed a mass with 
pleural invasion and multiple small nodules in the bilateral 
lungs. Ultrasound-guided percutaneous transthoracic lung 
biopsy revealed adenocarcinoma. Geﬁ  tinib (250 mg/day) 
was initiated. The RLL tumor decreased in size signiﬁ  cantly 
two months after treatment (Figure 1B). Both serum CEA 
and CA-199 decreased, from 4,178 ng/ml to 9.1 ng/ml 
and from 464 U/ml to 22 U/ml, respectively. However, the 
patient could not tolerate the severe side effects, including 
diarrhea, erythematous papules over the nasolabial areas 
and buttocks, and paronychia with granulation on ﬁ  ngers. 
Geﬁ  tinib was withdrawn for two weeks. Then, she received 
geﬁ  tinib at 250 mg on alternate days. These side effects 
became tolerable, and geﬁ  tinib at 250 mg/day was resumed. 
Nine months after initiating geﬁ  tinib, chest radiography 
revealed progression of tumor (Figure 1C). At this time, 
chest CT revealed tumor progression with an endobronchial 
tumor in the right middle bronchus. Geﬁ  tinib was 
discontinued. After obtaining written, informed consent 
from the patient, a CT-guided lung biopsy specimen was 
obtained. Pathological analysis conﬁ  rmed the presence 
of adenocarcinoma. This patient received subsequent 
chemotherapy for advanced lung cancer.
Genomic DNA was extracted from the tumor specimen 
of an original lung biopsy and a progressive tumor biopsy 
specimen. The tyrosine kinase domain (exons 18–21) was 
ampliﬁ  ed and sequenced. Mutations were also checked 
against the corresponding DNA from blood lymphocytes at 
the diagnosis of lung cancer. The original diagnostic biopsy 
specimen contained a thymidine to guanine mutation at 
nucleotide 2573 of exon 21, resulting in L858R. In the second 
biopsy, an additional single-base change from cytosine to 
thymidine was identiﬁ  ed at nucleotide 2369 in exon 20, 
resulting in T790M. 
This report strengthens the evidence of T790M as an 
acquired geﬁ  tinib-resistant mutation. Geﬁ  tinib responsiveness 
results in large part from the drug’s effective inhibition of 
essential antiapoptotic signals transduced by the mutant 
receptor, and L858R is the most commonly detected 
mutation [2–5]. The T790M mutation is rarely found in 
tumors from patients not treated with either geﬁ  tinib or 
erlotinib, and could be discovered only in progressing 
tumors, in addition to a primary drug-sensitive mutation in 
EGFR. A non-small-cell lung cancer cell line bearing both 
T790M and L858R mutations was approximately 100-fold less 
sensitive to geﬁ  tinib or erlotinib, and did not show inhibition 
of tyrosine phosphorylation in vitro [1]. 
Pao et al. and Kobayashi et al. identiﬁ  ed four cases with 
lung adenocarcinoma harboring pre-existing mutations 
of EGFR as delL747–E749 plus A750P, delE746–A750, or 
delL747–S752, prior to the use of geﬁ  tinib or erlotinib 
[1,6]. All of them had exposure to previous systemic 
chemotherapies and took a small-molecule tyrosine kinase 
inhibitor as the second- or third-line therapy, then all 
acquired a second mutation T790M in the following months 
after disease progression. In the case of our patient, the 
patient received no prior systemic chemotherapy, and 
we identiﬁ  ed an initial geﬁ  tinib-sensitizing L858R EGFR 
mutation, followed by a T790M mutation concomitantly with 
L858R in the biopsy taken from the growing tumor nine 
months after geﬁ  tinib use. Though it is unlikely that prior 
chemotherapy led to the development of T790M mutation, 
given the complexity of EGFR mutation, further studies are 
still required to elucidate the role of T790M mutation in the 
context of EGFR mutations.  
This correspondence was peer reviewed. 
DOI: 10.1371/journal.pmed.0020269.g001
Figure 1. Chest Radiography 
Chest radiography shows a large mass in the RLL before geﬁ  tinib 
treatment (A), and marked decrease in tumor size two months after 
geﬁ  tinib was initiated (B). This tumor progressed nine months after 
geﬁ  tinib treatment (C).
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